Related Experiment Video
Updated: Mar 15, 2026
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
HER2 Alterations in Non-Small Cell Lung Cancer: Emerging Perspectives on the Therapeutic Landscape
Paola Muscolino1, Elena Fassi2,3, Diego Signorelli4
1School of Specialization in Medical Oncology, Department of Human Pathology "G. Barresi", University of Messina, 98125 Messina, Italy.
Abstract:
Over the past decade, significant achievements in elucidating the molecular pathogenesis of non-small cell lung cancer (NSCLC) have catalyzed a paradigm shift from empiric therapies to precision oncology. In this context, HER2 alterations, including protein overexpression, gene amplification, and activating mutations, constitute distinct molecular subsets within NSCLC. In the past few years, targeted therapeutic modalities such as antibody-drug conjugates (ADCs), particularly trastuzumab deruxtecan (the first agent to be granted FDA approval for HER2-mutant NSCLC), alongside selective tyrosine kinase inhibitors (TKIs), including zongertinib and sevabertinib, have demonstrated robust systemic efficacy and notable intracranial penetration. This comprehensive review delineates the molecular landscape and clinical phenotypes of HER2-altered NSCLC, synthesizes interim and mature data from ongoing clinical trials evaluating anti-HER2 therapies, and critically examines efficacy and safety results from different classes of targeted agents. Further research is crucial to uncover potential mechanisms of resistance in NSCLC with HER2 mutations and define sequencing or combinatorial strategies pertinent to optimizing individualized patient management.
Insights
Targeted therapies like antibody-drug conjugates and tyrosine kinase inhibitors show promise for non-small cell lung cancer (NSCLC) with HER2 alterations. Research continues to optimize treatment strategies for this specific NSCLC subset.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Precision oncology has transformed non-small cell lung cancer (NSCLC) treatment, moving beyond empiric therapies.
- HER2 alterations (overexpression, amplification, mutations) define distinct molecular subsets within NSCLC.
- Targeted therapies are emerging as effective treatments for HER2-altered NSCLC.
Purpose of the Study:
- To review the molecular landscape and clinical phenotypes of HER2-altered NSCLC.
- To synthesize data from clinical trials evaluating anti-HER2 therapies.
- To critically examine the efficacy and safety of targeted agents for HER2-altered NSCLC.
Main Methods:
- Comprehensive literature review of molecular pathogenesis and clinical phenotypes.
- Synthesis of interim and mature data from ongoing clinical trials.
- Critical examination of efficacy and safety data for targeted agents.
Main Results:
- Antibody-drug conjugates (ADCs) and tyrosine kinase inhibitors (TKIs) demonstrate systemic and intracranial efficacy.
- Trastuzumab deruxtecan is FDA-approved for HER2-mutant NSCLC.
- Agents like zongertinib and sevabertinib show notable clinical activity.
Conclusions:
- Targeted anti-HER2 therapies represent a significant advancement in NSCLC treatment.
- Further research is needed to understand resistance mechanisms and optimize treatment sequencing or combinations.
- Individualized patient management strategies are crucial for HER2-altered NSCLC.
More Related Videos
05:17Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:38Mitogens and the Cell Cycle
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers